(-)-9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido<1,2,3-de><1,4>benzoxazine-6-carboxylic acid BF2-chelate | 129306-33-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (-)-9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido<1,2,3-de><1,4>benzoxazine-6-carboxylic acid BF2-chelate
• 英文别名: 9,10-difluoro-2,3-dihydro-3(S)-methyl-7-oxo-7H-pyrido<1,2,3-de><1,4>benzoxazine-6-carboxylic acid BF2-chelete；(3S)-(-)-9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido-[1,2,3-de][1,4]-benzoxazine-6-carboxylic acid difluoroborate ester；S-(-)-9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido-[1,2,3-de][1,4]-benzoxazine-6-carboxylic acid difluoroborate ester；(3S)-9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1.2.3-de][1,4]benzoxazine-6-carboxylic acid-difluoroborane complex；(3S)-9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid difluoroboran complex；(3S)-9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1.2.3-de][1,4]benzoxazine-6-carboxylic acid difluoroboron complex；(S)-6-(((difluoroboryl)oxy)carbonyl)-9,10-difluoro-3-methyl-2H-[1,4]oxazino[2,3,4-ij]quinolin-7(3H)-one；difluoroboranyl (2S)-6,7-difluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylate
• CAS: 129306-33-8
• 化学式: C₁₃H₈BF₄NO₄
• 分子量: 329.015
• InChiKey: CIZIGPOVKCJAQK-YFKPBYRVSA-N

物化性质

• 沸点：
  408.1±55.0 °C(Predicted)
• 密度：
  1.53±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于乙腈（少许）、DMSO（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.31
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (-)-9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido<1,2,3-de><1,4>benzoxazine-6-carboxylic acid BF2-chelate 在 盐酸 、 乙醇 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 乙腈 为溶剂， 生成 10-<3-(R)-(1-(S)-aminoethyl)-1-pyrrolidinyl>-9-fluoro-3-(S)-methyl-2,3-dihydro-7-oxo-7H-pyrido<1,2,3-de>-1,4-benzoxazine-3-carboxylic acid
  参考文献：
  名称：

  新型含腈氟喹诺酮类抗菌剂的合成及生物学评价。

  摘要：

  据报道，几种新的含弱碱性胺类的含腈氟喹诺酮类药物具有减少的hERG（人醚-go-go-go基因）通道抑制作用的潜力，如多芬替利试验所测。新的氟喹诺酮类药物对革兰氏阳性和革兰氏阴性菌株均有效，包括耐甲氧西林的金黄色葡萄球菌和耐氟喹诺酮的肺炎链球菌。通过克隆形成性测试，几种类似物还显示出较低的人类遗传毒性潜力。具有良好的体外活性和体外安全性的化合物22和37（分别命名为PF-00951966和PF-02298732）在大鼠中也显示出良好的药代动力学特性。

  DOI：

  10.1016/j.bmcl.2007.01.090

文献信息

• Tri-, tetra-substituted-3-aminopyrrolidine derivative
  申请人：Takahashi Hisashi

  公开号：US20060264428A1

  公开（公告）日：2006-11-23

  A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided. The compound provided is represented by following formula (I): wherein R 1 and R 2 represent hydrogen atom, or the like; R 3 represents an alkyl group containing 1 to 6 carbon atoms, or the like; R 4 and R 5 independently represents hydrogen atom, an alkyl group containing 1 to 6 carbon atoms, or the like, with the proviso that R 4 and R 5 do not simultaneously represent hydrogen atom; or the substituents R 4 and R 5 together represent (a) a 3- to 6-membered cyclic structure including the carbon atom shared by R 4 and R 5 to form a spirocyclic structure with the pyrrolidine ring; R 6 and R 7 independently represents hydrogen atom, an alkyl group containing 1 to 6 carbon atoms, or the like; R 8 represents a halogen-substituted alkyl group containing 1 to 6 carbon atoms, or the like; X 1 represents hydrogen atom or a halogen atom; A represents nitrogen atom or a moiety represented by formula (II):

  提供了一种喹诺酮合成抗菌剂和治疗感染的药物，对革兰氏阳性和革兰氏阴性细菌均表现出广谱和强效的抗菌活性，并且具有很高的安全性。所提供的化合物由以下式（I）表示： 其中R1和R2代表氢原子，或类似物；R3代表含有1至6个碳原子的烷基基团，或类似物；R4和R5独立地代表氢原子，含有1至6个碳原子的烷基基团，或类似物，但R4和R5不同时代表氢原子；或取代基R4和R5一起代表（a）包括由R4和R5共享的碳原子形成螺环结构与吡咯烷环形成螺环结构的3至6成员环结构；R6和R7独立地代表氢原子，含有1至6个碳原子的烷基基团，或类似物；R8代表含有1至6个碳原子的卤代烷基基团，或类似物；X1代表氢原子或卤原子；A代表氮原子或由式（II）表示的基团。
• [EN] C-7 ISOXAZOLINYL QUINOLONE/NAPHTHYRIDINE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS DE C-7 ISOXAZOLINYL QUINOLONE/NAPHTHYRIDINE CONVENANT COMME AGENTS ANTI-BACTÉRIENS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010093341A1

  公开（公告）日：2010-08-19

  The present invention relates to C-7 isoxazolyl quinoline/naphthyridine derivatives useful as antimicrobial compounds, pharmaceutical compositions comprising said derivatives and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.

  本发明涉及C-7异噁唑基喹啉/萘啶衍生物，可用作抗微生物化合物，包括含有这些衍生物的药物组合物以及将这些衍生物和药物组合物用作抗病原微生物的抗微生物剂，特别是对抗耐药菌。
• [EN] QUINOLONE ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTERIENS A LA QUINOLONE
  申请人：WARNER LAMBERT CO

  公开号：WO2005049602A1

  公开（公告）日：2005-06-02

  Compounds of formula (I) wherein A is formula (II), formula (III) or formula (IV), and B is formula (V), formula (VI), or formula (VII), can be used in a variety of applications including use as antibacterial agents.

  式(I)的化合物中，其中A是式(II)，式(III)或式(IV)，B是式(V)，式(VI)或式(VII)，可用于各种应用，包括用作抗菌剂。
• C-7 Isoxazolinyl Quinolone / Naphthyridine Derivatives Useful as Antibacterial Agents
  申请人：Macielag Mark J.

  公开号：US20090029980A1

  公开（公告）日：2009-01-29

  The present invention relates to C-7 isoxazolyl quinoline/naphthyridine derivatives useful as antimicrobial compounds, pharmaceutical compositions comprising said derivatives and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.

  本发明涉及C-7异噁唑基喹啉/萘啶衍生物，可用作抗微生物化合物，包括含有该衍生物的药物组合物以及将该衍生物和药物组合物用作抗病原微生物的抗微生物剂，特别是对抗耐药微生物。
• Synthesis and Structure-Activity Relationships of 7-(3-(1-Aminoalkyl)pyrrolidinyl)- and 7-(3-1-aminocycloalkyl)pyrrolidinyl)quinolone Antibacterials.
  作者：Youichi KIMURA、Shohgo ATARASHI、Masanobu TAKAHASHI、Isao HAYAKAWA

  DOI：10.1248/cpb.42.1442

  日期：——

  series of 7-[3-(1-aminoalkyl and 1-aminocycloalkyl)-1-pyrrolidinyl] quinolones have been prepared and their biological properties evaluated. Among them, 1-(S)-aminoalkyl derivatives exhibited potent antibacterial activities against gram-positive and gram-negative organisms. They had moderate lipophilicity and high aqueous solubility compared to their aminomethyl counterparts; e.g., the 3-(1-aminoethyl)-1-pyrrolidinyl

  已经制备了一系列的7- [3-（1-氨基烷基和1-氨基环烷基）-1-吡咯烷基]喹诺酮并评估了它们的生物学特性。其中，1-（S）-氨基烷基衍生物对革兰氏阳性和革兰氏阴性生物显示出有效的抗菌活性。与氨基甲基同类物相比，它们具有中等的亲脂性和较高的水溶性。例如，3-（1-氨基乙基）-1-吡咯烷基化合物（83）的药代动力学特性优于其氨基甲基对应物（6）。